Newly diagnosed patients with mild COPD run the risk of being undertreated with only short-acting bronchodilators or overtreated with inhaled corticosteroids. What is the preferred regimen for these patients?
According to the GOLD guidelines, the patient with mild COPD (Group A) should receive bronchodilator therapy—preferably maintenance therapy with a long-acting bronchodilator. While rescue therapy with short-acting bronchodilators provides symptomatic improvement, long-acting bronchodilators provide additional benefits such as improved lung function, reduced exacerbations, and improved quality of life.
When patients are prescribed both rescue and maintenance therapy, long-acting bronchodilators have been shown to reduce the use of short-acting bronchodilators. This is clinically important because overuse of short-acting bronchodilators is associated with increased risk of exacerbations and mortality. Overuse may be a marker of worsening disease, and the increased mortality risk may also be due to cardiovascular side effects.
The GOLD guidelines recommend maintenance therapy for patients with mild COPD. They do not state a preference between long-acting muscarinic antagonists (LAMAs) and long-acting beta 2 agonists (LABAs). However, a recent 2023 study published in Vol 9 Issue 3 of ERJ Open Research by the ERS, found that LAMAs provide greater improvement in tissue oxygenation, COPD Assessment Test score, and St George Respiratory Questionnaire score than LABAs. In addition, LAMAs are associated with a lower incidence of exacerbations and adverse events than LABAs. Based on these findings, LAMAs may be the preferred choice.
What is your preferred regimen for the initial treatment of mild COPD? When would you consider a LAMA vs. a LABA based on the new findings?
-
Robert Tanaka1yrLAMA, with prn albuterol HFA. In the rare case of intolerance or lack of formulary coverage would consider once a day LABA
-
ANTHONY FRITZ1yrSABA plus LAMA/LABA is preferred
-
SENTHIL RAGHAVAN1yrMy initial therapy would be LAMA. along with smoking cessation
-
Thomas Hawkey1yrMy initial rx for mild copd would be a saba and a lama/laba
-
Mitchell Ahrens1yrLAMA typically first option if low burden of symptoms, if more signifcant symptoms then LABA/LAMA options to reduce dyspnea etc.
-
Darin Skaudis, Physician1yrSmoking cessation if that's ongoing. LAMA/LABA is usually my preferred initial inhaler.
-
Darin Skaudis, Physician1yrSmoking cessation if that's ongoing. LAMA/LABA is usually my preferred initial inhaler.
-
Matthew Hegewald1yrLAMA is the 1st choice for patients Group A COPD; However, cost for a LABA/LAMA combination is similar to a LAMA so why not use a combination LABA/LAMA?
-
Seth Ivins1yrIt has typically been a LAMA , since the approval of Spiriva, (along with prn albuterol). I sometimes used combivent, but not for quite some time.
-
Vincent Gimino1yrfor those patients who are eligible for single therapy, I typically choose a LAMA. There are more options, and there is always a fear (reasonably more so on part of the patient) for jitteriness or tachycardia side effects. As a bonus typically we also have samples of LAMAs for medication trials and for inhaler instruction
-
Richard Nguyen1yrwhile both LAMAs and LABAs are effective for the initial treatment of mild COPD, a LAMA might be preferred in patients with a history of exacerbations or specific clinical considerations.
-
BRITTANY LITTLE1yrLAMA
-
Kenneth Chinsky, Chest Diseases/Allegheny Health Network1yrLama first but Laba lama if more than minor symptoms
-
Bing Xue1yrCertainly LAMA is the first line of maintenance inhaler for this group of patients.
-
Matthew Shore, Family Medicine1yrLAMA unless contraindicated or a tolerability issue
-
CHRISTOPHER COMPTON1yrI prefer patient to stop smoking if smoking and LAMA is my first choice to control symptoms.